𝗧𝗵𝗲 𝗻𝗲𝘅𝘁 𝘀𝘁𝗲𝗽? 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝘆 𝗮𝗻𝗱 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀. Diagnostics are so, so important. But without therapeutic options... Would it make sense to increase the The Michael J. Fox Foundation for Parkinson's Research Therapeutic Pipeline grant opportunity, either in number awarded or maximum amount available? Two million dollars over two years is a lot of money, but it does not seem that this will necessarily be enough when figuring in manufacturing costs and the kind of oversight necessary for the FDA to accept the data as a step towards the market. Let's keep the focus on Parkinson's - including therapeutics. 𝙎𝙞𝙜𝙣 𝙪𝙥 𝙛𝙤𝙧 𝙢𝙮 𝙬𝙚𝙚𝙠𝙡𝙮 𝙣𝙚𝙬𝙨𝙡𝙚𝙩𝙩𝙚𝙧 𝙖𝙩 𝙋𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣𝙨𝘿𝙞𝙨𝙚𝙖𝙨𝙚.𝙗𝙡𝙤𝙜 https:parkinsonsdisease.blog #parkinsons #parkinsonsdisease The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation Parkinson's UK Critical Path Institute (C-Path)
Just over a year ago, there was a major breakthrough in Parkinson’s disease (PD) research – the discovery of a tool that could detect abnormal alpha-synuclein protein in the spinal fluid of people living with PD even before onset of symptoms. In our recent “Parkinson’s Science POV” podcast episode, MJFF’s Maggie McGuire Kuhl, vice president of research engagement leads a discussion with Brian Fiske, PhD and Mark Frasier, PhD, MJFF co-chief science officers. They discuss the ways the biomarker discovery helps reveal connections with other brain diseases and holds the promise to make clinical trials cheaper, faster and more effective. Listen now: https://bit.ly/3LoS0FK